9.94
0.43 (4.52%)
| Penutupan Terdahulu | 9.51 |
| Buka | 9.51 |
| Jumlah Dagangan | 586,056 |
| Purata Dagangan (3B) | 1,838,216 |
| Modal Pasaran | 587,603,904 |
| Harga / Pendapatan (P/E TTM) | 4.95 |
| Harga / Pendapatan (P/E Ke hadapan) | 8.76 |
| Harga / Jualan (P/S) | 4.57 |
| Harga / Buku (P/B) | 2.73 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2026 |
| Margin Keuntungan | -226.64% |
| Margin Operasi (TTM) | -26.28% |
| EPS Cair (TTM) | -1.94 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 495.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 150.74% |
| Nisbah Semasa (MRQ) | 3.02 |
| Aliran Tunai Operasi (OCF TTM) | -61.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -39.23 M |
| Pulangan Atas Aset (ROA TTM) | -27.73% |
| Pulangan Atas Ekuiti (ROE TTM) | -204.78% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Zevra Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.00 |
|
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.69% |
| % Dimiliki oleh Institusi | 65.42% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |